|Assessment Status||Assessment process complete|
|Indication||Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.|
|Rapid review commissioned||02/06/2011|
|Rapid review completed||09/06/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended.|
|Full submission received from Applicant||03/11/2011|
|NCPE assessment completed||13/03/2012|
|NCPE assessment outcome||Reimbursement not recommended at the submitted price.|
The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.
The HSE has approved reimbursement following confidential price negotiations; March 2014.